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Abstract
Invasion of human immunodeficiency virus (HIV) into the central and peripheral nervous system
produces a wide range of neurological symptoms, which continue to persist even with adequate
therapeutic suppression of the systemic viremia. The development of therapies designed to prevent
the neurological complications of HIV require a detailed understanding of the mechanisms of
virus penetration into the nervous system, infection, and subsequent neuropathogenesis. These
processes, however, are difficult to study in humans. The identification of animal lentiviruses
similar to HIV has provided useful models of HIV infection that have greatly facilitated these
efforts. This review summarizes contributions made from in vitro and in vivo studies on the
infectious and pathological interactions of feline immunodeficiency virus (FIV) with the nervous
system. In vivo studies on FIV have provided insights into the natural progression of CNS disease
as well as the contribution of various risk factors. In vitro studies have contributed to our
understanding of immune cell trafficking, CNS infection and neuropathogenesis. Together, these
studies have made unique contributions to our understanding of (1) lentiviral interactions at the
blood–cerebrospinal fluid (CSF) barrier within the choroid plexus, (2) early FIV invasion and
pathogenesis in the brain, and (3) lentiviral effects on intracellular calcium deregulation and
neuronal dysfunction. The ability to combine in vitro and in vivo studies on FIV offers enormous
potential to explore neuropathogenic mechanisms and generate information necessary for the
development of effective therapeutic interventions.
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Introduction
Rapid penetration of human immunodeficiency virus (HIV) into the central nervous system
(CNS), viral persistence in the brain, and neurological disease progression continue to be
significant problems associated with HIV infection (McArthur et al. 2005). Even with
current antiretroviral regimens, the prevalence of cognitive–motor dysfunction continues to
increase in HIV-infected individuals. Therapeutic interventions are badly needed but the
development of effective treatments has proven to be difficult because of the unique
characteristics of CNS infection. Within the CNS, lentiviruses such as HIV are thought to
replicate in cells of monocyte lineage including perivascular macrophages and microglia
(Brinkmann et al. 1993; Dow et al. 1999; Fischer-Smith et al. 2001; Gonzalez-Scarano and
Martin-Garcia 2005; Gorry et al. 2001; Hein et al. 2000; Koenig et al. 1986; Lane et al.
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1996; Petito 2004; Williams et al. 2001; Zenger et al. 1997). Control of virus replication in
the brain has been difficult as a result of the poor penetration of most antiretroviral drugs
across the blood–brain and blood–cerebrospinal fluid (CSF) barriers as well as the presence
of mechanisms for active transport of these compounds from the brain. Thus, CNS disease
continues (Anthony et al. 2005; Neuenburg et al. 2002; Sacktor et al. 2002) even with
suppression of both the systemic and CSF viral load (Cysique et al. 2005). To develop
effective therapeutic interventions we need to better understand (1) how the virus gains
access to the brain, (2) when and how CNS pathogenesis begins, (3) the unique properties of
the brain viral reservoir, and (4) the mechanisms that underlie neuronal damage. Because of
the difficulty of exploring these processes in humans, animal models have played an
essential role in this endeavor.
Within 2 years of the identification of the HIV, two similar, naturally occurring animal
lentiviruses were isolated. Simian immunodefciency virus (SIV), isolated from macaques
(Kanki et al. 1985), and feline immunodeficiency virus (FIV) (Pedersen et al. 1987), isolated
from domestic cats, are genetically and functionally similar to HIV including similar cell
tropism and the ability to produce a severe acquired immune deficiency syndrome (AIDS).
The study of infection in these animals has provided significant insights into the
mechanisms of pathogenesis applicable to our understanding and treatment of HIV (for
reviews, see Gendelman et al. 2005). In this review, we summarize in vitro and in vivo
studies on FIV infection that have helped to shed light on early immune cell trafficking,
CNS infection, the progression of CNS disease, and the mechanisms of neuronal
dysfunction. Representative examples are used throughout to illustrate many of the key
findings from these studies.
FIV: A lentivirus similar to HIV
FIV infection is seen in domestic and feral cat species worldwide (Carpenter and O’Brien
1995) with estimates of seroprevalence rates in the domestic cat ranging from approximately
1% to 14%. The genomic organization of FIV is similar to, although less complex than
HIV-1 (Olmsted et al. 1989; Talbott et al. 1989); it has also been suggested, based on
phylogenetic analysis, that FIV may represent a more primitive lentivirus that has evolved
independently of HIV and SIV (Elder and Phillips 1993; Olmsted et al. 1989). FIV, like
HIV-1(Livingstone et al. 1996; Potter et al. 2003), infects CD4+ and CD8+T lymphocytes
(Brown et al. 1991; English et al. 1993) as well as monocyte-derived cells (Beebe et al.
1994; Brunner and Pedersen 1989; Dow et al. 1992). Natural transmission of the virus is
thought to occur predominantly via bites received during fighting or sexual activity,
although efficient transmission can also occur after vaginal inoculation (Burkhard et al.
2002; Burkhard and Dean 2003; Jordan et al. 1998; Obert and Hoover 2002). FIV is also
transmitted vertically to offspring with a rate of 22–50% (Allison and Hoover 2003b; O’Neil
et al. 1996) with transmission occurring both in utero (~20% infection rate) and during
nursing (~13% infection rate) (O’Neil et al. 1996). However, offspring infected by this route
often failed to show a sustained infection with FIV (Allison and Hoover 2003a) or clinical
disease (Wasmoen et al. 1992).
Infection results in a clinical syndrome initially characterized by an inversion of the CD4/
CD8 ratio, followed by a progressive decline in circulating CD4+T cells (Ackley et al. 1990;
Tompkins et al. 1991; Torten et al. 1991) and a sustained increase in activated CD8+T cells
(Bucci et al. 1998; Gebhard et al. 1999; Hoffmann-Fezer et al. 1992; Novotney et al. 1990;
Willett et al. 1993). These CD8+T cells are thought to play an important role in the control
of systemic and brain infection (Bucci et al. 1998; Gebhard et al. 1999; Hohdatsu et al.
2000; Hohdatsu et al. 2002). Eventually, a severe immunodeficiency develops with
accompanying opportunistic infections (English et al. 1994). In addition, FIV also infects B
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lymphocytes (English et al. 1993) in vivo, thereby exhibiting a slightly broader host cell
range than HIV-1(Levy 1993). Although most primary isolates of FIV will infect both T
lymphocytes and monocytes, productive replication in vivo is largely restricted to FIV-
infected T lymphocytes (Beebe et al. 1994; Brunner and Pedersen 1989; Dow et al. 1992;
Dow et al. 1999). In contrast to HIV-1, FIV uses CD134 as a primary receptor instead of
CD4 (de Parseval et al. 2004; Shimojima et al. 2004). Like HIV-1, FIV uses the alpha
chemokine receptor, CXCR4, as a coreceptor (Egberink et al. 1999; Hosie et al. 1998;
Richardson et al. 1999; Willett et al. 1997). Human and feline CXCR4 share significant
homology and the receptor combination of CD134 and CXCR4 for FIV would be expected
to confer similar tropism and mechanisms of infection as HIV. Although feline peripheral
blood mononuclear cells (PBMCs) have been shown to express a CCR5 receptor mRNA
with 68% homology to human CCR5 (Kovacs et al. 1999), the utilization of this receptor for
infection is controversial (Johnston and Power 2002; Lerner and Elder 2000; Willett et al.
2002).
FIV infection results in the synthesis of neutralizing antibodies that are targeted to various
envelope domains with variable loop 3 and the carboxy terminus of envelope consisting of
major antigenic sites (de Ronde et al. 1994; Lombardi et al. 1995; Richardson et al. 1996).
As with HIV-1, the cross-reactivity of sera for various FIV strains is highly variable (de
Ronde et al. 1994; Del Mauro et al. 1998; Hohdatsu et al. 1997; Osborne et al. 1994;
Richardson et al. 1996) and specific mutations can confer resistance (Siebelink et al. 1995).
The ability of antibodies to target the FIV virion depends heavily on the exposure of
epitopes on the envelope surface (Richardson et al. 1996), indicating that neutralizing
antibodies face similar challenges for FIV as for HIV. Neutralizing antibodies are also found
in the CSF of infected cats (Dow et al. 1990; Phillips et al. 1994). These antibodies differed
from the profile in serum and showed a tendency to preferentially recognize envelope versus
other FIV proteins (e.g., gag proteins). These observations suggested a local synthesis of the
CSF antibodies. However, the presence of antibodies did not correlate well with the level of
detectable virus or CNS disease. The extent to which neutralizing antibodies control virus in
the CSF is not known, but studies showing the development of profiles of FIV envelope
expression in the CSF that are unique from plasma are consistent with a role of local
antibodies in variant selection (Liu et al. 2006b). In this case, a subset of FIV variants
present in plasma appears within the CSF with the infrequent emergence of a variant that is
not present in plasma. However, the restriction of FIV variants within the CSF does not
appear to involve a specific selection because no consistent pattern of variants appears in the
CSF.
Although there are some notable differences between HIV-1 and FIV, the pathogenesis of
FIV infection in the brain and systemic tissues is remarkably similar to HIV-1. Studies on
FIV pathogenesis have contributed to our understanding of the nature of lentiviral infections
on many fronts (Burkhard and Dean 2003). These contributions are highlighted by the recent
approval of the first animal lentivirus vaccine (Huang et al. 2004; Pu et al. 2001; Uhl et al.
2002). In addition, studies on FIV have contributed to our understanding of the mechanisms
of immune suppression (Vahlenkamp et al. 2005) and have been used for the evaluation of
antiretroviral therapeutics (Arai et al. 2002; Bisset et al. 2002; de Rozieres et al. 2004;
Egberink et al. 1990; Hartmann et al. 1992; Hayes et al. 1995), the testing of virus
penetration of mucosal barriers (Burkhard et al. 2002; Burkhard and Dean 2003; D’Cruz et
al. 2004; Obert and Hoover 2002), the efficacy of topical antiviral treatments (D’Cruz et al.
2004), and the analysis of the efficacy of entry inhibitors (Garg et al. 2004). These studies
highlight the diverse contributions of FIV to lentiviral pathogenesis, which cannot all be
adequately covered in this review. In the following sections, contributions that the FIV
model has made to our understanding of CNS pathogenesis are summarized.
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FIV penetration into the brain and CSF
FIV trafficking across the blood–brain barrier
Like the primate lentiviruses, neurotropism of FIV is thought to be largely attributable to the
penetration of infected monocytes/macrophages into the brain. Because of the tissue barriers
and the relative lack of systemic immune cells, the penetration and dissemination of virus
into the brain and CSF is unique from other tissues. There are two primary cell-associated
entry pathways for FIV: (1) monocyte trafficking through the blood–brain barrier and (2)
monocyte/macrophage trafficking across the blood–CSF barrier. The potential contribution
of T cells is less well understood. In vitro models of the blood–brain barrier have been used
to explore the mechanisms that control immune cell trafficking across the brain
endothelium. These studies have used fetal feline microvascular endothelial cells grown on
transwell insert membranes containing 3- to 5-μm pores. By combining these cultures with
astrocytes and/or microglia, the role of parenchymal cells in the trafficking of PBMCs
across the endothelium has been evaluated (Hudson et al. 2005). Monocytes, CD4+T cells,
CD8+T cells, and B cells were all observed to cross the endothelium although the ability to
cross was highly dependent on the presence of astrocytes. This positive role of astrocytes
was unexpected inasmuch as they are instrumental in the formation of the blood–brain
barrier. Exposure of the cultures to FIVNCSU1 did not induce any preferential trafficking of
monocytes, in agreement with previous trafficking studies on human monocytes infected
with HIV-1 (Persidsky et al. 1997). Of all the major PBMC subsets, only CD8+T cells were
subject to positive regulation when the feline cultures were exposed to FIV. The addition of
microglia to the cultures (feline endothelium + astrocytes + microglia) suppressed the
trafficking of T cells, B cells, and monocytes (Hudson et al. 2005). The suppression of
monocyte trafficking by the microglia was partially reversed when the cultures were
inoculated with FIV. These results indicated that astrocytes facilitate trafficking whereas
microglia exercise inhibitory control over the astrocytes. The broad range of trafficking cells
seen in vitro is consistent with in vivo trafficking studies that have shown early invasion of T
cells and B cells within the brain of cats 8–10 weeks after infection with FIVGL8 (Ryan et al.
2005). Provirus has been detected in the brain as early as 2–4 weeks postinoculation,
suggesting that the early immune cell trafficking carries virus into the CNS during the initial
systemic viremia (Poli et al. 1999; Ryan et al. 2003). FIV RNA was consistently recovered
in brain tissue at 10 weeks when the infiltration of mononuclear cells was at a peak,
suggesting that the trafficking cells fuel the virus production (Ryan et al. 2003). However,
both the tissue pathology and the viral loads decreased substantially over time, indicating a
significant recovery from this acute phase of infection. Tissue proviral burden was reduced
to zero by 23 weeks, further suggesting that the acute phase of infection with FIVGL8 did not
establish a persistent viral reservoir. Still, FIV-infected cats eventually develop a relatively
high, sustained proviral burden in the brain (Macchi et al. 1998; Pistello et al. 1994). These
and other studies also showed that a high proviral burden did not predict a high viral burden
because it has often been difficult to demonstrate active virus replication in brain tissue
carrying a significant proviral burden. The control of virus production in brain is not well
understood and remains an important area of research.
FIV trafficking across the blood–CSF barrier
In addition to penetration across the blood–brain barrier, large amounts of virus may also
penetrate into the brain via the blood–CSF barrier. This barrier differs from the blood–brain
barrier in several respects. First, there are no tight junctions at the vascular endothelium.
This allows easier penetration of virus and immune cells. Second, the stromal region
between the vascular endothelium and the choroidal epithelium contains a large population
of macrophages as well as dendritic cells. Third, the blood–CSF barrier is formed by tight
junctions between the cuboidal epithelial cells of the choroid plexus. In studies of mouse
Meeker Page 4













choroid plexus, the epithelium has been shown to constitutively express the adhesion
molecules ICAM-1 and VCAM-1 (Steffen et al. 1996). In addition, ICAM-1, VCAM-1, and
MAdCAM-1 were increased in response to inflammatory stimuli (Steffen et al. 1996). The
expression of these adhesion molecules suggests that the epithelium exerts substantial
control over trafficking of cells into the ventricular system and CSF, particularly under
inflammatory conditions. Adhesion to the epithelium may facilitate penetration of cells
through the tight junctions in much the same fashion as penetration of the blood–brain
barrier. Thus, the choroid plexus is poised to be an important interface between the systemic
immune system and the brain. However, the functional role of the choroid plexus in immune
cell trafficking across the blood–CSF barrier is still poorly understood.
In addition to circulating immune cells, the trafficking of cells across the epithelium most
likely includes resident choroid plexus macrophages. In the in vivo study on FIV infection of
the brain by Ryan et al. (2005), a relatively robust infiltration of mononuclear cells was seen
in the choroid plexus, meninges, and subarachnoid space as early as 4 weeks postinfection.
This was accompanied by the appearance of low copy numbers of FIV RNA in the CSF,
reinforcing the view that the blood–CSF barrier in the choroid plexus may be a significant
site of the earliest immune cell and virus invasion. However, the relationship between the
systemic viremia and virus in the CSF is complex. Detailed studies of plasma and CSF viral
kinetics indicate that the transfer of virus is not a highly predictable process. As an example,
Fig. 1 illustrates the time course of viremia in two cats intraperitoneally inoculated with
FIVNCSU1. In most cases, the appearance of virus in CSF immediately follows the
appearance in plasma (e.g., Cat #1). However, in Cat #2, virus appearance in the CSF is
delayed several weeks in spite of the fact that it received the same inoculation and developed
a rapid plasma viremia almost identical to Cat #1. The reason for the variation between
plasma and CSF viral kinetics is still not well understood, but these analyses have indicated
that virus penetration into the CSF can vary dramatically between animals. This variable
delay may, in part, account for the low correlations typically seen when temporally matched
plasma and CSF samples are compared. Although such correlations (e.g., r =0.310 for FIV
RNA in CSF versus plasma) can reach statistical significance, they account for only about
10% of the variability in FIV-infected cats. CSF virus is certainly linked to plasma virus, but
more work is needed to fully understand the constraints on virus exchange from the blood to
the CSF compartment.
It has also been suggested based on studies of HIV that virus in the choroid plexus and CSF
is likely to be a mix of virus from peripheral and CNS origin (Chen et al. 2000; Ellis et al.
2000; Strain et al. 2005). Studies on FIV have provided support for this view. High CSF/
plasma ratios are relatively common in cats, suggesting a robust local virus production
within the CSF and adjacent tissues (Liu et al. 2006a). Inversions of the FIV CSF/plasma
ratio (CSF > plasma) often occur at times corresponding to the acute productive infection
seen in brain parenchyma 4–10 weeks after infection (Ryan et al. 2003). Studies on FIV
envelope diversity during the early stages of infection have suggested that the virus that first
appears in the CSF is similar to plasma (Liu et al. 2006b). Over time, there can be
significant divergence in the pattern of variants in the CSF versus plasma including the rare
appearance of unique variants. These observations suggest that once established in the brain,
local FIV synthesis and evolution can contribute to the pattern of variants seen in the CSF.
Further evidence for the evolution of virus within the brain/CSF comes from the
identification of neurovirulent brain-specific FIV sequences from the CSF (Power et al.
1997; Power et al. 1998). The evolution of sequences specific to the CNS also reinforces the
view that FIV adapts to the neural environment much the same as HIV-1. As with HIV-1,
many questions remain regarding compartmentalization, viral evolution, and local control of
viral replication in the CNS. The FIV model provides a versatile system for the investigation
of these processes through all stages of pathogenesis.
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FIV neurotropism and neuropathogenesis
FIV neurotropism
FIV penetration into the brain initiates a long and slow decline in CNS function with few
overt symptoms until the cats develop AIDS. As the cats become immune deficient,
approximately 20% will develop significant neurological deficits. Early studies on FIV
tropism demonstrated that virus could be recovered from brain and CSF of infected cats
(Dow et al. 1990; Macchi et al. 1998; Power et al. 1997). In vitro studies of CNS cell
tropism indicate that FIV can infect feline astrocytes (Billaud et al. 2000; Danave et al.
1994; Dow et al. 1990; Kawaguchi et al. 1992; Yu et al. 1998), microglia (Dow et al. 1990;
Hein et al. 2000; Kawaguchi et al. 1992), choroid plexus macrophages (Bragg et al. 2002a),
and perhaps brain microvascular endothelial cells (Steffan et al. 1994). In vivo studies
indicate that most virus production in the CNS is maintained by macrophages and microglia
(Dow et al. 1999; Hein et al. 2000).
Although microglia and macrophages are primary targets of FIV in the brain and choroid
plexus, they support a relatively low-grade productive infection(Bragg et al. 2002a; Hein et
al. 2000, 2001). However, the addition of PBMCs to infected microglia or macrophages can
lead to a robust productive infection (Bragg et al. 2002a; Hein et al. 2000, 2001), indicating
efficient transfer of virus to T cells. Interactions between macrophages and T cells could be
particularly prominent within perivascular regions and the choroid plexus. Perivascular
localization of infected macrophages is a common finding for HIV, SIV, and FIV infections.
In addition, many studies have documented lentiviral transcripts within the choroid plexus of
infected hosts (Beebe et al. 1994; Bragg et al. 2002a; Chen et al. 2000; Falangola et al.
1995; Petito et al. 1999). These studies suggested that the infected perivascular and choroid
plexus macrophages are poised to interact with trafficking T cells in a fashion that could
facilitate virus production. Such interactions might also promote the evolution of viral
strains adapted for growth in both cell lineages, as suggested by the admixture of systemic
and CNS viral genotypes seen in HIV-1-infected choroid plexus (Chen et al. 2000). The
trafficking of virus and/or infected macrophages into the CSF might also contribute directly
to pathogenesis, but the functional implications of macrophage and virus trafficking through
the blood–CSF barrier are just beginning to be explored.
Although astrocytes can be infected with FIV in vitro, the role of astrocyte infection in vivo
has been less clear because primary isolates of FIV are much less infectious than cell
adapted strains and little evidence is available to support a widespread infection of
astrocytes in the brain. However, the potential significance of astrocyte infection in vivo is
underscored by studies of Gavrilin et al. (2002), showing that astrocytes could be infected in
vitro when exposed to PBMC previously infected with FIVMD. In contrast, direct
inoculation with cell-free wild-type FIVMD failed to infect the astrocytes. The subsequent
passage of the virus from the PBMC–astrocyte cultures to fresh astrocyte cultures produced
a new CXCR4-dependent, astrocyte-tropic strain of FIV (FIVMD-A). This evolution of the
virus in response to cell–cell interactions has important implications for the development of
reservoirs of viral quasispieces in the brain as well as their potential contribution to
pathogenesis.
FIV neuropathogenesis
One of the early questions regarding lentiviral invasion of the CNS was whether CNS
pathogenesis was progressive in nature. Because infection and pathogenesis could be closely
followed in cats over time, a number of studies were performed to evaluate the evolution of
CNS disease. These studies, using a variety of endpoints, showed that damage begins during
the asymptomatic stages of disease but, as in humans, does not become severe until the
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development of AIDS. Neurological symptoms have been documented in cats
experimentally inoculated with the primary isolates, FIVMD (Phillips et al. 1994; Podell et
al. 1993, 1997, 1999; Prospero-Garcia et al. 1994), the infectious molecular clone, FIVPPR
(Phillips et al. 1996, 2000), FIVNCSU1 (unpublished data), and the neurovirulent CSF-
derived isolate, FIVV1CSF (Power et al. 1998). Symptoms observed in these cats included
abnormal, stereotypic motor behaviors, anisocoria, increased aggression, increased cortical
slow wave activity in quantitative electroencephalograms, prolonged latencies in brainstem
evoked potentials, delayed righting and pupillary reflexes, decreased nerve conduction
velocities, marked changes in sleep architecture, and deficits in cognitive–motor functions
(Phillips et al. 1994, 1996; Podell et al. 1993, 1997; Prospero-Garcia et al. 1994; Steigerwald
et al. 1999). Using proton magnetic resonance spectroscopy (MRS), Power et al. (1998) and
Podell et al. (1999) demonstrated reductions in the concentrations of the neuronal marker, N-
acetyl-aspartate (NAA) and the NAA/choline or NAA/creatine ratio within the brains of
FIV-infected cats. Measurement of visual and auditory evoked potentials has also provided a
sensitive index of progressive neurological dysfunction (Phillips et al. 1996; Podell et al.
1997). In each case, neurological deficits could be detected at relatively early stages of
disease with progression over time. An understanding of the nature of the gradual CNS
disease progression has become increasingly important as it most likely reflects the type of
disease currently seen in patients on antiretroviral therapy.
FIV neuropathology
Most FIV-infected cats show characteristic neuropathological changes similar to patients
infected with HIV-1, although typically less severe than HIV-1 encephalitis. Diffuse
astrogliosis and microgliosis, myelin pallor, microglial nodules, and rare, multinucleated
giant cells have been observed in brains of FIV-infected cats (Abramo et al. 1995; Boche et
al. 1996; Hurtrel et al. 1992; Poli et al. 1997; Silvotti et al. 1997). Astrogliosis, microgliosis,
and a diffuse perivascular monocyte infiltration are most commonly seen (Fig. 2). In
addition, a significant neuronal loss has been seen within the cortex and basal ganglia of
FIVNCSU1-infected cats beginning as early as 2–3 years postinfection (Meeker et al. 1997;
Power et al. 1997), whereas the cats were still asymptomatic. Large pyramidal cells within
layers two, three, and five of the frontal/parietal cortex and large cells within the striatum
appeared to be most vulnerable to early damage (Meeker et al. 1997). The loss of neurons in
the parietal lobe and striatum correlated with decreases in the CD4/CD8 ratio, suggesting a
close relationship to the systemic immune response (Meeker et al. 1997). An average 32%
decrease in the number of large neurons was similar to numbers reported for HIV (Wiley et
al. 1991). However, it is important to note that as other neurons were minimally affected (as
with HIV), the decrease in total neuron density was a modest 2.3%. Although the extent of
neuronal loss continued to increase with systemic disease severity, the general picture was
one of a slow, progressive degeneration. Further support for FIV-associated
neurodegeneration was provided by Jacobson et al. (1997), who found that large pyramidal
neurons in cortical layers three and five show an increased immunoreactivity for
neurofilament protein, and Koirala et al. (2001), who showed decreased expression of
MAP-2 and GAD. These latter measures may reflect neuronal dysfunction that is likely to be
a more sensitive index of CNS disease than cell death (Dou et al. 2003; Nagra et al. 1993;
Toggas et al. 1996; Zheng et al. 2001). These observations also reinforce the idea that much
of the pathology associated with FIV and HIV infection is potentially reversible. Reports of
increased cortical synaptophysin immunoreactivity at early stages of disease progression
(Meeker et al. 1997) and increased Timms staining (sprouting) in the hippocampus of FIV-
infected cats (Mitchell et al. 1999) further suggest that compensatory processes may help to
maintain neural function during the asymptomatic stages of disease. These observations
emphasize the dynamic interplay between destructive and intrinsic neuroprotective
responses during the course of disease.
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The appearance of neuronal loss and neuronal dysfunction in asymptomatic cats is
consistent with the early appearance of altered sleep architecture at 10–12 months
postinoculation (Prospero-Garcia et al. 1994), cortical atrophy by MRI at 12 months (Podell
et al. 1993), decreased NAA and NAA/choline at 14 months (Podell et al. 1999), motor and
spatial memory deficits at 12 months (Steigerwald et al. 1999), and the appearance of
neurotoxic activity in the CSF of FIV-infected cats as early as 4 months (Bragg et al.
2002b). These findings clearly indicate the need for early therapeutic intervention to
suppress neurodegeneration and highlight the potential utility of the feline model for the
development and testing of such interventions.
Cellular mechanisms of FIV neurotoxicity
In vitro characterization of neurotoxicity
One of the advantages of the FIV model is the ability to perform both in vitro and in vivo
experiments. This allows the efficient translation of in vitro information on cellular
mechanisms to development of therapeutics in the naturally infected host. Most cell types
within the feline CNS have been successfully cultured including neurons, astrocytes,
microglia, macrophages, endothelial cells, and choroid plexus epithelium. Studies that have
examined the interactions of FIV and macrophage-derived toxins with primary forebrain
neural cultures have led to a number of important insights into the mechanisms of
neuropathogenesis. Early studies using the primary isolate, FIVNCSU1, demonstrated
relatively rapid effects on neuronal function and survival in culture (Meeker et al. 1996).
Inoculation of primary feline neural cultures with FIV alone produced minimal cell death.
However, the addition of a small, normally subtoxic concentration of glutamate (20 μM)
resulted in swelling of neurons within 20 min followed by death of a subset of neurons
(Meeker et al. 1996). The presence of FIV shifted the concentration–effect curve for
glutamate toxicity approximately threefold to the left, indicating an increase in the neuronal
sensitivity to the glutamate. The effects of FIV were blocked by an N-methyl-D-aspartate
(NMDA) glutamate receptor antagonist. Toxicity increased progressively over the first week
of exposure to FIV, suggesting the cumulative release of soluble toxic factors. Small
amounts of FIV provirus were detected in some of these cultures at 17–24 days
postinoculation, but no evidence of productive infection was observed during the period of
toxin generation, which peaked at approximately 6 days. Studies using FIV envelope protein
from the PPR strain reproduced most of the toxic features of live virus (Bragg et al. 1999;
Gruol et al. 1998). The toxic effects were not induced by the envelope protein derived from
FIV34TF10, a less neurovirulent strain (Bragg et al. 1999). As with the live virions, the
purified FIVPPR envelope protein exhibited little intrinsic toxicity, but facilitated neuronal
swelling, cell death (Meeker et al. 1996) and NMDA-evoked calcium entry into the cell
(Gruol et al. 1998). Similar toxicity profiles were seen when cultured neurons were exposed
to conditioned medium from FIVNCSU1-infected choroid plexus macrophages (Bragg et al.
2002b). Like HIV-1, infection of macrophages (Giulian et al. 1990; Pulliam et al. 1991;
Xiong et al. 1999; Yeh et al. 2000; Zheng et al. 1999b) leads to the release of substances into
the culture medium, which are toxic when applied to neuronal cultures. These experiments
clearly demonstrated that the destructive inflammatory interactions of FIV with
macrophages and microglial-enriched neural cultures recapitulated the effects of HIV and
illustrated that toxin production did not depend on significant virus production.
FIV and intracellular calcium homeostasis
A diverse range of HIV-associated, macrophage-derived neurotoxins with various actions
have been proposed (Gonzalez-Scarano and Martin-Garcia 2005; Jones and Power 2006). In
general, the mechanisms of toxicity are thought to involve aberrant activation of various
receptors and signal transduction pathways by viral proteins or macrophage-derived
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substances. The actions of these substances lead to a toxic accumulation of intracellular
calcium, oxidative stress, and generation of proapoptotic signals. Many of these pathways
have been the target of therapeutic strategies designed to protect neurons (Perry et al. 2005;
Turchan et al. 2003). Control of intracellular calcium has been an important focus of many
of these efforts.
Because excessive intracellular calcium accumulation is widely considered a final common
pathway leading to neuronal dysfunction and death, Bragg et al. (2002c) used feline neural
cultures to evaluate the relative contribution of various extra- and intracellular sources of
calcium to neuronal death in the presence of macrophage- or microglial-derived toxins. In
these experiments, cultured feline neurons were exposed to infectious virions (FIVNCSU1) or
conditioned medium from choroid plexus macrophages previously inoculated with
FIVNCSU1. Both challenges resulted in very small acute increases in intracellular calcium
followed by a gradual rise to high levels. The conditioned medium typically provoked a
greater toxic response than cell-free FIV virions, consistent with the idea that the
macrophages are a primary source of the toxins. An example of the intracellular calcium
response in neurons exposed to FIV virions isolated from the CSF of an infected cat is
illustrated in Fig. 3a. A cluster of neurons and a large microglial (MG) cell adjacent to a
neuron (arrow) is shown at times ranging from 0 to 40 min after exposure. A few neurons
show a small acute calcium response (0.17 min), whereas most have a negligible response.
After approximately 16 min, neuronal calcium begins to rise and by 40 min some cells show
high calcium. Typical responses of individual neurons exposed to FIV in the presence or
absence of the sodium channel antagonist, tetrodotoxin (TTX), are illustrated in Fig. 3b.
Although a small acute calcium response is seen, no delayed accumulation of calcium is
seen in the absence of synaptic transmission, emphasizing the importance of neuronal
activity for the gradual deregulation of calcium. Microglia in the cultures also respond to the
virus or macrophage-conditioned medium with a calcium increase although responses of
individual microglia tend to be highly variable. Sustained exposure of cultured neurons to
FIV results in dendritic beading, fragmentation, and the death of a subset of neurons. This
neuronal pathology can be seen with MAP-2 staining, as illustrated in Fig. 4, and is similar
to changes seen in the brain of patients with HIV encephalitis (Masliah et al. 1997).
As noted previously, exposure to virus, viral proteins, or macrophage-conditioned medium
all lead to enhanced glutamate receptor activation and accumulation of intracellular calcium.
Although there is strong evidence implicating glutamate receptors in the neuropathogenesis,
the specific actions of putative toxins are still not well defined. On the one hand, studies
have demonstrated that macrophages release glutamate and other substances that may
directly stimulate glutamate receptors. On the other hand, numerous studies have indicated
that glutamate receptors are indirectly modulated via undefined mechanisms. To better
appreciate the role of glutamate receptor activation in the FIV model, we compared the
response of neurons in macrophage-conditioned medium to the neuronal response to a
moderate concentration of glutamate (100 μM). A comparison of these conditions would
give an indication of the relative excitotoxic potency of the conditioned medium. Typical
neuronal responses to macrophage-conditioned medium (macrophage–FIV) or 100 μM
glutamate are illustrated in Fig. 5. Several important observations came from these
experiments. First, the acute increase in the calcium signal was much smaller (5–35%) than
that seen following application of a moderate concentration of glutamate (~100–200%
increase), indicating that, under these conditions, the toxins did not have a pathologically
significant direct excitatory effect on the neurons. The small acute response that was seen
most likely reflected the presence of small concentrations of excitatory substances released
from the macrophages. Second, although neurons exposed to the macrophage toxins showed
a small acute response, a large delayed calcium rise is still seen (often larger than that seen
following a glutamate challenge). This type of response is uniquely different from a classical
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excitotoxic response that is driven by the strong acute depolarization and calcium entry with
subsequent development of a glutamate receptor-independent delayed calcium deregulation
(Tymianski et al. 1993; Tymianski 1996). In contrast to glutamate excitotoxicity, virus and
macrophage-derived toxins could induce a delayed calcium deregulation in the absence of a
powerful acute stimulation. These observations suggested that there was an underlying
dysfunction that was responsible for the development of pathological increases in
intracellular calcium. This dysfunction would be expected to synergize with secretion of
excitatory substances, inhibition of glutamate uptake, and processes that indirectly facilitate
NMDA glutamate receptor function to encourage the accumulation of intracellular calcium.
Thus, although the neuronal pathology may involve different pathways, they share a
common endpoint in the generation of a delayed calcium deregulation. Finally, the delayed
increase in intracellular calcium was not restricted to neurons. A subset of microglia also
showed delayed increases in intracellular calcium (often very large) and astrocytes showed
very small delayed increases (not shown) (Bragg et al. 2002c). Thus, although neurons are
highly susceptible, all cells appear to be affected by the toxins. These observations further
suggested the FIV-associated dysfunction may involve a general process common to many
cell types.
If FIV exposure does not give rise to a strong excitotoxic glutamate response, what then is
responsible for the observed increases in neuronal responsiveness to glutamate and the
delayed calcium deregulation? Two observations in the feline neural cultures helped to
provide a possible explanation (Bragg et al. 2002c). First, examination of the response to a
brief pulse of glutamate in cultures inoculated with FIV, illustrated in Fig. 6a, not only
showed a greater peak calcium response to the glutamate but also a delay in the recovery to
baseline. The rate of recovery can be estimated from the slope of the plot of the log of the
fluorescence at each time point (F) relative to the peak (F 0) versus time. A considerable
slowing of the initial recovery rate is evident in the kinetics plot in Fig. 6b. The eventual
recovery to baseline suggests that a single pulse of glutamate is not sufficient to establish a
sustained rise in calcium. Similar effects have subsequently been reported after incubation of
rat cortical neurons with CSF from HIV-infected patients (Meeker et al. 1999b, 2005) or
CSF from FIV-infected cats (unpublished data), suggesting the presence of similar toxic
processes in vivo. In companion experiments, antagonists that block ligand-gated calcium
entry, voltage-gated calcium entry, intracellular calcium release, or synaptic transmission
were all found to have neuroprotective efficacy during a 24-h exposure to medium collected
from FIV-treated choroid plexus macrophages. Although the NMDA receptor antagonist 2-
amino-5-phosphonopentanoic acid (AP-5) showed the greatest neuroprotection (80%),
antagonists of voltage-gated calcium entry (nimodipine, omega-conotoxin), internal IP3
receptor-mediated calcium release at the endoplasmic reticulum (xestospongin C),
phospholipase C-linked G proteins (pertussis toxin), and synaptic activity (TTX), all showed
partial neuroprotective efficacy ranging from 21% to 66% (Bragg et al. 2002c). These
observations paralleled the findings from similar in vitro studies with HIV proteins and
human macrophage conditioned medium (Haughey et al. 1999; Holden et al. 1999; Lo et al.
1992; Zheng et al. 1999a, b). The broad efficacy of such a diverse array of antagonists
suggested that all major sources of calcium contributed to neuropathogenesis. Furthermore,
partial protection afforded by TTX in this (Bragg et al. 2002c) and other paradigms (Hegg
and Thayer 1999; Lo et al. 1992) indicated that much of the toxicity was dependent on
synaptic activity. This observation indicated that a single “hit” with viral proteins or
macrophage-derived excitotoxins, while perhaps contributing to the calcium accumulation,
was not solely responsible for the long-term calcium deregulation. Together, these findings
suggested a defect in a common downstream pathway that would facilitate calcium
accumulation in response to all routes of calcium entry. The most general downstream
pathways that might account for the above findings are those responsible for the recovery of
basal intracellular calcium levels through the export of calcium from the cytosol. Such a
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deficit would be highly consistent with the decreased calcium recovery in Fig. 6 (see also
Bragg et al. 2002c).
Potential targets of macrophage-derived toxins that participate in the export of calcium from
the cytosol include calcium transporters or exchangers at the plasma membrane, the
endoplasmic reticulum calcium ATPase, or the mitochondrial uniporter (Bragg et al. 2002c).
The characteristics of each recovery mechanism are summarized in Fig. 7. Recent studies
with HIV-infected human CSF have suggested that the sodium–calcium exchanger (NCX) is
the most likely cause of the calcium destabilization (Meeker et al. 2005). In these studies,
the function of each calcium transporter was blocked and the deficit compared with the
calcium deregulation seen in response to toxic HIV+ human CSF (Meeker et al. 2005). Only
blockade of the NCX with benzamil or reversal of the sodium gradient (elimination of the
driving force for exchange activity) were able to recapitulate the gradual rise in intracellular
calcium seen with the HIV+ CSF. In addition, blockade of the NCX suppressed the rate of
recovery of intracellular calcium after a brief pulse of glutamate. This deficit in the ability to
export excess intracellular calcium would be expected to synergistically increase the
magnitude of the intracellular calcium rise regardless of the source of calcium entry into the
cytosol. Thus, it provides a common mechanism that would facilitate calcium accumulation
in response to a variety of activation pathways. Even relatively modest increases in synaptic
activity may lead to a gradual buildup of calcium if the calcium entry exceeds the limited
capacity of the plasma membrane ATPase. Neuronal death would be expected only under
conditions that provoke robust calcium entry into the cytosol. This scenario provides a
consistent explanation for the neuroprotective effects of diverse receptor and channel
antagonists (including TTX) and helps to explain why therapeutic agents targeted to any one
source of calcium mobilization would have limited efficacy.
Astrocytes and neuropathogenesis
As noted above, and illustrated in several in vitro studies (Bragg et al. 2002c; Gruol et al.
1998; Meeker et al. 1997), exposure of neural cultures to FIV enhances glutamate-mediated
responses. We have hypothesized that this enhancement is attributable to a loss of calcium
export by the NCX. However, the loss of NCX activity would not be apparent in the absence
of receptor stimulation (i.e., no calcium signaling). Thus, the calcium overload in cells must
be due to a combination of calcium mobilization and decreased calcium export. Indeed,
numerous studies have implicated increased NMDA receptor activation in the pathogenesis
(Epstein and Gelbard 1999; Gemignani et al. 2000; Gruol et al. 1998; Haughey et al. 2001;
Kolson 2002; Lipton et al. 1991; Lipton 1992; Self et al. 2004; Toggas et al. 1996; Yeh et al.
2000). One prominent mechanism hypothesized to lead to enhancement of glutamatergic
activity is the suppression of glutamate uptake by astrocytes (Fine et al. 1996). Glutamate
transporters on astrocytes are responsible for the uptake of extracellular glutamate from the
synaptic cleft. Failure of amino acid transporters results in prolonged exposure of neurons to
glutamate and enhanced excitation. Support for this argument has been provided by reports
of increased concentrations of glutamate in extracts prepared from brains of FIV-infected
cats (Power et al. 1997) and the ability of FIV infection to inhibit uptake of glutamate by
astrocytes in vitro (Yu et al. 1998). In these latter studies, feline astrocytes harboring a low-
grade productive infection with the 34TF10 strain of FIV suffered a 50–60% reduction in
the ability to transport glutamate (Yu et al. 1998). Given that astrocytes can be a target for
infection by FIV (Danave et al. 1994; Dow et al. 1990; Zenger et al. 1995) and display a
high density of FIV binding sites (Meeker et al. 1999a), including CXCR4 expression
(Nakagaki et al. 2001), it is reasonable to postulate that virus in brain could induce a
widespread inhibition of glutamate uptake that increases the levels of neuronal excitation.
The extent of this effect in vivo is still unclear. The relatively poor infection of astrocytes in
vivo by wild-type FIV has raised questions regarding the role of astrocytes in CNS
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pathogenesis. However, recent studies, summarized above, raise the possibility that the
interaction of infected PBMC with astrocytes in vitro may be capable of generating
astrocyte-tropic variants of FIV (Gavrilin et al. 2002). These observations will have
important implications for CNS infection if similar interactions are shown to exist in vivo. It
is also possible that deficits in sodium–calcium exchange in astrocytes and microglia may
contribute to their dysfunction by altering calcium homeostasis. Calcium increases are
observed in these cells under the same conditions that lead to neuronal calcium
destabilization. The function of the NCX has not been explored in these cells and much
remains to be done to determine the extent of the CNS dysfunction attributable to a loss of
exchange activity in nonneuronal cells.
Interactions between drugs of abuse and lentiviral neuropathogenesis
The feline model of lentiviral pathogenesis is well suited for the study of drug interactions
with viral pathogenesis as well as potential screening of therapeutic agents. It has been used
to explore the interactions of both opiates and methamphetamine with infection. Multiple
acute doses of morphine, designed to mimic human abuse patterns, were shown to delay the
progression of FIV-induced disease (Barr et al. 2000, 2003). Methamphetamine, on the other
hand, has been shown to increase FIV replication in cultured astrocytes when the infection is
mediated by cell–cell interactions (Gavrilin et al. 2002). No effects were seen on direct
infection of astrocytes or PBMC with cell-free virus. The result of these latter studies was an
increased proviral burden in astrocytes, but not an increase in virus production. The impact
of the interactions of methamphetamine with FIV in vivo are also beginning to be explored
by taking advantage of the ability to image the feline brain with reasonable resolution.
Proton magnetic resonance studies have shown decreased creatine and choline and
elevations in GABA in methamphetamine-treated cats (Cloak et al. 2004). These early
studies are beginning to generate valuable clinical information on the interactions between
drugs of abuse and lentiviral infections.
Conclusion
FIV infection of the nervous system shares many common features with HIV including
common coreceptor usage, similar cellular targets, rapid penetration of the CNS, evolution
of neurovirulent FIV strains, and a diffuse inflammatory response with a progressive CNS
pathogenesis. Differences between FIV and HIV include a more simplified virus structure, a
different primary receptor, and a reduced severity of neuropathogenesis. In spite of the
differences, the systemic and CNS endpoints of infection are remarkably similar. In vivo
studies with FIV have provided insights into the natural progression of the disease in brain
and a means to evaluate interactions between the virus and factors that increase the risk of
infection and neurodegeneration. Results from in vitro studies of the effects of virus, viral
proteins, and macrophage-derived toxins in primary feline neural cultures strongly parallel
similar studies with HIV. These studies have (1) led to new insights into the role of
astrocytes and microglia in immune cell trafficking, (2) provided valuable information on
early infection, viral diversification, and disease progression in the CNS, (3) explored the
impact of drugs of abuse on infection and pathogenesis, (4) fostered a greater understanding
of the potential importance of the choroid plexus blood–CSF barrier as a site of virus entry,
and (5) defined potential mechanisms that lead to the loss of neuronal calcium homeostasis.
The ability to investigate the pathogenesis of FIV in specific-pathogen-free cats in parallel
with in vitro studies of cultured feline cells provides the opportunity for translational studies
that should facilitate the design and evaluation of new therapeutic strategies for the
treatment of HIV-associated CNS disease.
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Example of the variable relationship between plasma and CSF viral kinetics. The time
course for appearance of FIV RNA in the plasma and CSF is illustrated for two cats
inoculated intraperitoneally with 2×105 median tissue culture infectious doses of FIVNCSU1.
Although both cats developed almost identical plasma viremias, FIV appeared in the CSF of
Cat #1 at 2 weeks but was delayed until 6 weeks postinoculation in Cat #2.
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Example of neuropathology seen in cats infected with FIV. Infiltration of monocytic cells
positive for Mac387 has been seen in cats along the cortical surface (a), scattered through
the parenchyma of the basal ganglia (b, arrows), particularly along blood vessels (c) and
occasionally within and adjacent to the choroid plexus (d, arrows). In addition, diffuse
activated microglia, positive for feline CD18, can be detected in white matter (e), and
GFAP-immunoreactive astrocytes are prominent in the cortex (f) and other regions. These
observations indicate the presence of a low-grade diffuse inflammatory process that
becomes increasingly severe as the cats become immune deficient.
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Example of intracellular calcium changes in cultured feline neurons isolated from fetal
cortex–hippocampus. (a) A typical cluster of neurons is shown with low resting calcium at 0
min. The intensity of the Fluo-3 fluorescence is proportional to the cytosolic calcium
concentration and is color-coded from low to high as:
purple>blue>green>yellow>red>white. Addition of FIV isolated from the CSF of an
infected cat resulted in a small transient increase in a few neurons (0.17 min), followed by a
gradual increase beginning as early as 11 min. Moderately high calcium levels developed in
many neurons by 40 min. Individual neuronal responses can be quite variable, ranging from
minimal responsiveness to robust increases as seen in an isolated neuron (arrow) adjacent to
a microglial cell (MG). (b) Effect of synaptic activity on the calcium rise can be seen in a
comparison between neurons exposed to FIV in the presence or absence of 1 μM
tetrodotoxin (TTX). A small acute increase is seen in both preparations but the TTX-treated
neurons failed to show the delayed calcium deregulation, indicating that synaptic activity is
necessary for the delayed calcium rise.
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Dendritic damage seen in cultured neurons after 3 days of exposure to FIVNCSU1. (a) Mixed
culture of normal feline neurons stained with MAP-2 (green) and microglia stained for feline
CD18 (red). The nuclei are counterstained with bisbenzimide (blue). Astrocytes were not
stained. (b) Beading and fragmentation of dendrities (arrows) is the most common
pathological finding. Some increased cell death is apparent from condensed chromatin and
apoptotic nuclei (arrowheads) but it is substantially less extensive than the dendritic
changes.
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Comparison of the differential responses of cultured feline neurons after chronic application
of 100 μM glutamate or conditioned medium from FIV-infected choroid plexus
macrophages (macrophages+FIV). The medium was ultrafiltered (100 kDa) to remove free
virions and large viral proteins. Glutamate evokes a large acute increase in intracellular
calcium, which decreases and then begins to destabilize. The acute increase is not seen in
most neurons exposed to macrophage-conditioned medium (although a small subset of
neurons shows modest increases of approximately 10–40%). Even in the absence of a strong
acute response, the neurons exposed to the macrophage-conditioned medium show a gradual
delayed calcium deregulation.
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Characterization of the enhanced neuronal response to glutamate in mixed neural cultures
exposed to FIV. (a) A brief (2 s) pulse of 100 μM glutamate applied to FIV-treated cultures
(FIV+Glu) evokes a much larger neuronal calcium response than seen in neurons stimulated
with glutamate in the absence of FIV (Glu). The FIV-treated neurons also develop a calcium
plateau that delays recovery. (b) The rate of recovery of intracellular calcium can be
calculated from a plot of the log of the ratio of calcium at each time point (F) to peak
calcium (F 0) versus time. This analysis illustrates the dramatic decrease in the rate of
recovery in neural cultures exposed to FIV (FIV+Glu).
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Model depicting the major processes that control intracellular calcium homeostasis.
Cytosolic calcium can be taken up into endoplasmic reticulum by the sarcoplasmic–
endoplasmic reticulum ATPase (SERCA) or into mitochondria by the uniporter. The
endoplasmic reticulum normally maintains a high internal level of calcium and probably
does not have a primary role in the clearance of cytosolic calcium. The mitochondrial
uniporter exhibits an exponential increase in transport when the cytosolic calcium
concentration exceeds ~1 μM. Most of the routine control of intracellular calcium is
probably handled by the plasma membrane calcium ATPase (PMCA) and the sodium–
calcium exchanger (NCX). PMCA is a high-affinity, low-capacity pump that uses ATP to
drive the export of calcium from the cell. NCX is a low-affinity, high-capacity exchanger
that uses the Na+ gradient across the plasma membrane to exchange 3 Na+ for 1 Ca2+.
Recent studies designed to isolate the function of each process have suggested that loss of
NCX function may be responsible for the gradual destabilization of intracellular calcium in
neurons exposed to HIV, FIV, or associated toxins.
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